Sana Biotechnology, INC

Sana Biotechnology stockholders re-elected three Class II directors and ratified the appointment of Ernst & Young LLP as the company's independent auditor.

Sana Biotechnology, Inc. has raised approximately $69.0 million in net proceeds through the sale of 21,607,878 shares of common stock.

Sana Biotechnology announced first quarter 2026 financial results, highlighting a strategic collaboration with Mayo Clinic for type 1 diabetes therapy development and progress across multiple drug candidates.

Sana Biotechnology, Inc. has reclassified a Class I director to Class III to achieve a more balanced board structure.

Sana Biotechnology announced a stock purchase agreement with Mayo Clinic for up to $50 million in common stock, bolstering its operational runway into 2027.

Sana Biotechnology announced its fourth quarter and full year 2025 financial results, highlighted positive clinical progress in type 1 diabetes and blood cancers, and amended its at-the-market offering program to raise up to $150 million.

Sana Biotechnology, Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing a net loss of $47.2 million and highlighting progress in its cell engineering platforms while acknowledging substantial doubt about its ability to continue as a going concern.

Sana Biotechnology, Inc. reported a significant reduction in net losses for the nine months ended September 30, 2025, driven by strategic portfolio prioritization and workforce reductions, while advancing key cell engineering programs.

Sana Biotechnology reports reduced net losses and a strengthened cash position following strategic portfolio prioritization and recent capital raises, despite ongoing development-stage challenges.

Sana Biotechnology announces Q1 2025 results with a net loss of $49.4 million and expresses substantial doubt about its ability to continue as a going concern without additional funding.

Sana Biotechnology reports its Q3 2024 financial results and announces a strategic shift to prioritize certain clinical programs and reduce workforce.

Sana Biotechnology's second quarter 2024 results show a decrease in operating expenses and a net loss of $50.3 million, alongside updates on clinical trials and strategic focus.

Sana Biotechnology's 2024 10-K filing highlights advancements in its cell engineering platforms and clinical trials, particularly in type 1 diabetes, while also acknowledging substantial doubt about its ability to continue as a going concern without additional funding.

Sana Biotechnology's annual 10-K filing highlights its strategic focus on ex vivo hypoimmune cell therapies, ongoing clinical trials, and investments in manufacturing capabilities.

Sana Biotechnology Director Hans Edgar Bishop reported the vesting of 6,297 restricted stock units on July 6, 2026.

Director Patrick Y. Yang was granted 90,000 stock options in Sana Biotechnology, Inc. as part of standard equity compensation.

Director Robert L. Rosiello was granted 90,000 stock options in Sana Biotechnology, Inc. as part of a standard equity incentive.

Director Alise Reicin was granted 90,000 stock options in Sana Biotechnology, Inc. as part of standard equity compensation.

Director Richard Mulligan was granted 90,000 stock options in Sana Biotechnology, Inc. as part of a standard equity incentive.

Director Hans Edgar Bishop was granted 90,000 stock options in Sana Biotechnology, Inc. as part of standard equity compensation.

Sana Biotechnology, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 4, 2026, with key proposals including director elections and auditor ratification.

Sana Biotechnology will hold its annual meeting of stockholders virtually on June 5, 2025, to elect directors and ratify the appointment of Ernst & Young LLP as its independent accounting firm.

Sana Biotechnology announces its 2025 Annual Meeting of Stockholders to be held virtually on June 5, 2025, featuring director elections and ratification of the independent accounting firm.

Sana Biotechnology will hold its annual stockholders meeting virtually on June 6, 2024, to elect directors and ratify the appointment of Ernst & Young LLP as its independent accounting firm.

Sana Biotechnology will hold its 2024 Annual Meeting of Stockholders virtually on June 6, 2024, to elect directors and ratify the appointment of its independent accounting firm.

RA Capital Management and its principals have filed a Schedule 13G reporting a 6.3% beneficial ownership stake in Sana Biotechnology, Inc.

BlackRock, Inc. has reported a 5.1% beneficial ownership stake in Sana Biotechnology Inc., holding 13,643,304 shares of common stock as of December 31, 2025.

ARCH Venture Funds and affiliated entities report a combined 17.2% beneficial ownership in Sana Biotechnology, Inc., with Robert Nelsen holding 17.3%.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a passive beneficial ownership of 4.9% of Sana Biotechnology, Inc.'s common stock as of March 31, 2025.

The Vanguard Group has filed an amended Schedule 13G, reporting a 4.81% passive beneficial ownership stake in Sana Biotechnology Inc. as of December 31, 2024.